ERBB2 and breast cancer: To investigate the features of the tumor microenvironment in endocrine‐resistant breast cancer, we first analyzed the RNA‐sequencing data (GSE20181) of ER+HER2– breast cancer patients treated with neoadjuvant endocrine therapy (letrozole) after 90 days, which could rule out other treatment interference.